Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:  Adolescent/Adult
Indications
 
General Reports
NVP/3TC 
NVP/EFV/DDI 
 NVP/Etravirine
NVP/TNF/EMT
NVP/STV/3TC
NVP/ZDV/DDI vs STV/DDI
NVP/ZDV/3TC
STV/DDI/NVP
Miscellaneous  Combinations		 Post-Exposure Prophylaxis
Dosing
Adherence
Treatment Strategies
Guidelines  


 

 
NVP Main Page Journal Main Page Main New/Newsworthy  Home Page
Last Update:  May 02, 2012
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
           
 
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
The HIV-CAUSAL Collaboration.
AIDS. 2012 Apr 26.
Abstract

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with
tenofovir/emtricitabine in treatment-naïve patients.
 Dejesus E, Mills A, Bhatti L, et al
Int J Clin Pract. 2011 Oct 14.
 Abstract

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate
and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
 Podzamczer D, Andrade-Villanueva J, Clotet B,  et al
HIV Med. 2011 Apr 24.
 Abstract

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
 Haïm-Boukobza S, Morand-Joubert L, Flandre P,  et al
AIDS. 2010 Dec 13.
 Abstract

Protein Adducts As Prospective Biomarkers of Nevirapine Toxicity.
 Antunes AM, Godinho AL, Martins IL, et al
Chem Res Toxicol. 2010 Sep 1
 Abstract

Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median
Time of 6 Years on Nevirapine.
 Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, et al
 Curr HIV Res. 2009 Sep;7(5):526-532
 Abstract

Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract

 
NVP/3TC
           
  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract 		 
NVP/3TC
           
  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract 		 
NVP/EFV/DDI
           
  Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily
regimen for patients with HIV infection.
 Jordan WC, Jefferson R, Yemofio F, et al
J Natl Med Assoc. 2003 Dec; 95(12): 1152-7.
 Abstract
NVP/Etravirine
           
  Susceptibility to Etravirine of HIV-1 subtype C isolates from Nevirapine/Efavirenz-experienced patients: comparative
interpretation of ANRS and STANFORD algorithms.
 Fleury HJ, Anquetil D, Deshpande A, et al 
AIDS Res Hum Retroviruses. 2012 Apr 20.
 Abstract
NVP/TNF/EMT
           
  Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine
as First-Line Therapy in Routine Clinical Practice.
 Vallecillo G, Domingo P, Mallolas J,  et al
AIDS Res Hum Retroviruses. 2011 Jul 26
 Abstract
NVP/STV/3TC
           
 
Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine:
A Preliminary Report on the Nigerian Antiretroviral Program.
 Idigbe EO, Adewole TA, Eisen G, et al  
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-69.
 Abstract
 
FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive
Patients Infected with HIV-1
 van Leth F , Phanuphak P Stroes  E , et al  
PLoS Medicine Vol 1, No 1
 Paper

FULL-TEXT PDF ARTICLE
 Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
 Yozviak JL, Eric Doerfler R, Woodward WC.
HIV Clin Trials 2001 Nov-Dec;2(6):474-476
 PDF Paper

Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors
Compared to HAART: A Meta-Analysis of Randomized Clinical Trials.
 Torre D, Tambini R, Speranza F, et al. 
HIV Clin Trials 2001 Mar-Apr;2(2):113-21
Abstract

Efficacy of nevirapine-based haart in hiv-1-infected, treatment-naive persons with high and
low baseline viral loads
 Raffi F, Reliquet V, Podzamczer D, Pollard RB.
 HIV Clin Trials 2001 Jul-Aug;2(4):317-22
Abstract

 
NVP/ZDV/DDI vs ZDV/DDI
           
  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients
with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.
 NIAID Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT, Hughes MD, Johnson VA, et al.
 Ann Intern Med 1996 Jun 15;124(12):1019-30
Abstract 		  
NVP/ZDV/3TC
           
  Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not
reflected in clinical outcomes in a 48-week randomized comparison with
abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
 Munderi P, Walker AS, Kityo C,  et al
HIV Med. 2010 Feb
Abstract 		  
STV/DDI/NVP
           
  Immunologic response to antiretroviral treatment with combined stavudine, didanosine
and nevirapine.
 Reliquet V, Robillard N, Perre P, et al
Presse Med 2001 Jul 7-3;30(23):1143-7
Abstract 		 
Miscellaneous Combinations
           
 
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or
lamivudine-containing regimens in HIV-infected subjects.
 Smith DE, Chan DJ, Maruszak H, Jeganathan S.
 Int J STD AIDS. 2011 Apr;22(4):228-30
 Abstract

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase
inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
 Mbuagbaw LC, Irlam JH, Spaulding A,  et al
Cochrane Database Syst Rev. 2010 Dec 8;12:CD004246.
 Abstract

Using of nevirapine is associated with intermediate and reduced response to etravirine among
HIV-infected patients who experienced virologic failure in a resource-limited setting.
 Kiertiburanakul S, Wiboonchutikul S, Sukasem C,  et al 
J Clin Virol. 2010 Feb 24
 Abstract

FULL-TEXT ARTICLE
 Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients:
multicentric observation cohort.
 Li T, Dai Y, Kuang J,  et al
PLoS ONE. 2008;3(12):e3918.
Paper
 
FULL-TEXT PDF ARTICLE
 Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among
HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and
fluconazole.
 Manosuthi W, Athichathanabadi C, Uttayamakul S, et al
BMC Infect Dis. 2007 Mar 12;7(1):14
Paper
 
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful
first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing
efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz,
or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
 Van Leth F, Phanuphak P, Ruxrungtham K, et al. 
Lancet. 2004 Apr 17;363(9417):1253-1263.
 Abstract

Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2-Class versus 3-Class
Regimens for the Treatment of Human Immunodeficiency Virus Type 1.
 Launay O, Gerard L, Morand-Joubert L
 Clin Infect Dis 2002 Nov 1;35(9):1096-105
 Abstract

Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside
reverse-transcriptase inhibitors.
Yozviak JL, Doerfler RE, Woodward WC.
Clin Infect Dis 2002 Feb 15;34(4):547-50
Abstract

FULL-TEXT PDF ARTICLE
 Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high
and low baseline viral loads.
 Raffi F, Reliquet V, Podzamczer D, Pollard RB, et al,
HIV Clin Trials 2001 Jul-Aug;2(4):317-22
 PDF Paper

 
Post-Exposure Prophylaxis
       
 
Tolerance of a Short Course of Nevirapine, Associated With 2 Nucleoside Analogues, in Postexposure
Prophylaxis of HIV.
Rey D, Partisani M, Hess-Kempf G, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1454-6.
Abstract

Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis.
Puro V, Soldani F, De Carli G, et al 
AIDS. 2003 Sep 5;17(13):1988-90.
 Abstract
Dosing
       
 
NEWS RELEASE
Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives CHMP
recommendation for approval.
 July 27,2011

A WEEK-IN-REVIEW FEATURED REPORT
 Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
 Calmy A, Vallier N, Nguyen A, Lange JM,  et al
Antivir Ther. 2009;14(7):931-938.
 Abstract

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
 Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
 Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.
 Abstract
Adherence
       
 
Home deliveries: Implications for adherence to nevirapine in a PMTCT programme in
rural Malawi.
 Kasenga F, Hurtig AK, Emmelin M.
AIDS Care. 2007 May;19(5):646-52.
 Abstract
Guidelines and Recommendations
United States      
United States
 
  FULL-TEXT PDF DOCUMENT
 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
 US DHHS
 November 3, 2008
Guidelines		  

 
NVP  Main Page Journal Main Page Main New/Newsworthy  Home Page

Nevirapine Journal Data
Adolescent/Adult Indications